NVUS - Enrollment underway in Novus Therapeutics' mid-stage AT-1501 trial in neuromuscular disease

The first subject has been enrolled in Novus Therapeutics' (NVUS) Phase 2a clinical trial evaluating anti-CD40L antibody, AT-1501 in adults with amyotrophic lateral sclerosis ((ALS)), a neurodegenerative neuromuscular disease resulting in the progressive loss of motor neurons that control voluntary muscles. Top-line data from this trial are anticipated in 2022. The endpoints of the study are safety and tolerability, and changes in pro-inflammatory biomarkers as well as neurofilament light chain. Exploratory clinical endpoints will also be assessed. Novus Therapeutics has completed a Phase 1a/1b single ascending dose trial in healthy volunteers and adults living with ALS.Pipeline overview: Shares down 8% premarket.

For further details see:

Enrollment underway in Novus Therapeutics' mid-stage AT-1501 trial in neuromuscular disease